Empresaria Group (EMR) Q2 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 TU earnings summary
28 Jul, 2026Executive summary
Net fee income for H1 FY 2026 increased by approximately 5% year-over-year despite challenging market conditions.
Adjusted profit before tax for H1 FY 2026 is expected to be up about 250% compared to the same period last year.
Full-year adjusted profit before tax is now forecast to be at least £5.2m, about 27% above market expectations.
Most brands delivered improved results, with IMS (Global Workforce Solutions) and Headway (Operational Outsourcing) performing particularly well.
Financial highlights
Net fee income rose by approximately 5% in H1 FY 2026 versus H1 FY 2025.
Adjusted profit before tax for H1 FY 2026 is up around 250% year-over-year.
Net debt remained stable at £17.0m as of 30 June 2026 (vs. £17.1m at 31 December 2025).
Outlook and guidance
Adjusted profit before tax for FY 2026 is expected to be at least £5.2m, exceeding market forecasts by about 27%.
Management remains optimistic about continued profitable growth despite ongoing market and geopolitical challenges.
Latest events from Empresaria Group
- Adjusted profit before tax surged 82% to £4.0m, with strong Offshore Services and US healthcare growth.EMR
H2 2025 - Adjusted PBT to exceed expectations; Offshore Services and US show strong growth amid tough markets.EMR
H2 2025 TU - Net fee income and profit rose in H1 2025, led by US and Offshore Services gains.EMR
H1 2025 - US and Offshore Services drove H1 net fee income growth, offsetting UK market weakness.EMR
H1 2025 TU - Net fee income fell 9% CC LFL, with cost controls supporting 2024 guidance despite market weakness.EMR
H1 2024 - Profit outlook cut as market headwinds persist, with strategic simplification ongoing.EMR
Trading Update - Net fee income fell 6% (CC LFL), but profit before tax should meet expectations.EMR
Trading Update - Profits and net fee income fell, but UK/US focus and non-core exits target debt elimination.EMR
H2 2024